Keeping Track: New MCL Treatment Calquence, Submissions Galore, And A Breakthrough Designation For GSK
Executive Summary
The latest drug development news and highlights from our US FDA Performance Tracker.
You may also be interested in...
Keeping Track: A Quintet Of Novel Approvals
The latest drug development news and highlights from our US FDA Performance Tracker.
CNS Treatments Highlight US FDA's Busy Pipeline Of Novel Agents For 2018
Rare disease and infectious disease candidates also are among the most common treatments in agency's review queue.
GSK's Oncology R&D Head: GSK2857916 'Proves We're Still Here And Serious'
GSK's promising anti-BCMA antibody-drug conjugate GSK2857916 shows the UK group remains a serious contender in the innovative cancer space, its oncology R&D head tells Scrip.